参考资料:
[1]中国国家药监局药品审评中心(CDE)官网.Retrieved June 7,2023, From https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c
[2]Bristol Myers Squibb Investor Event. Retrieved November 19, 2021, from https://s21.q4cdn.com/104148044/files/doc_presentations/2021/2021-BMS-Investor-Event-Presentation.pdf
[3]A phase I/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma. Retrieved Jan 31,2023, From https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e20043?af=R[4] 百时美施贵宝官网. From https://www.bms.com/researchers-and-partners/in-the-pipeline.html
本文来自药明康德内容团队,欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求,请联系wuxi_media@wuxiapptec.com。